IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: An immunohistochemical study

European Journal of Histochemistry

Volumn 57, Issue 1, 2013, Pages 36-40

  Silvia, Soddu ^a   Di Felice, E ^a   Cabras, S ^a   Castellanos, M E ^b   Atzori, L ^a   Faa, G ^a   Pilloni, L ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSIDAD CARLOS III DE MADRID   (Spain)

Author keywords

IGF II mRNA binding protein 3 (IMP 3); Keratoacanthoma; Squamous cell carcinoma

Indexed keywords

EID: 84874389243     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e6     Document Type: Article

References (54)

1. Nielsen Je, Cshristiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-70.
2. Müeller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14: 2729-33.
3. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188-95.
4. Wachter DL, Schlabrakowski A, Hoegel J, Kristiansen G, Hartmann A, Riener MO. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol 2011;35:873-7.
5. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-64.
6. Mhawech-Fauceglia P, Herrmann FR, Rai H, Tchabo N, Lele S, Izevbaye I, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2010;133:899-908.
7. Hammer NA, Hansen TO, Byskov AG, Rajpert-De Meyts E, Grøndahl ML, Bredkjaer HE, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005; 130:203-12.
8. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 2004;24:671-8.
9. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant'Agnese PA, Wang HL, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007;38:1178-83.
10. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007;38:555-63.
11. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, et al. Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 2012;48:3405-13.
12. Wang L, Li HG, Xia ZS, Lü J, Peng TS. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J 2010; 123:3554-8.
13. Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003;88:887-94.
14. Ozdemir NO, Türk NS, Düzcan E. IMP3 Expression in urothelial carcinomas of the urinary bladder. Turk Patoloji Derg 2011; 27:31-7.
15. Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 2008;21:431-7.
16. Clauditz TS, Wang CJ, Gontarewicz A, Blessmann M, Tennstedt P, Borgmann K, et al. Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2012;29:1-8.
17. Li HG, Han JJ, Huang ZQ, Wang L, Chen WL, Shen XM. IMP3 is a novel biomarker to predict metastasis and prognosis of tongue squamous cell carcinoma. J Craniofac Surg 2011;22:2022-5.
18. Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 2011;35:1638-45.
19. Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009;26:150-63.
20. Rook A, Whimster I. Keratoacanthoma-a thirty year retrospect. Br J Dermatol 1979;100:41-7.
21. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993;15:332-42; discussion 343-52.
22. Alyahya GA, Heegaard S, Prause JU. Malignant changes in a giant orbital keratoacanthoma developing over 25 years. Acta Opthalmol Scand 2000 Apr;78(2):223-5.
23. Gross DA. Metastasizing keratoacanthoma? Plast Reconstr Surg. 1979;63(2):258-9.
24. Grossniklaus HE, Wojno TH, Yanoff M, Font RL. Invasive keratoacanthoma of the eyelid and ocular adnexa. Ophthalmology 1996;103:937-41.
25. Pilloni L, Bianco P, Difelice E, Cabras S, Castellanos ME, Atzori L, et al. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Eur J Histochem 2011;55:e20.
26. McCullagh P, Nelder JA. Generalized Linear Models, 2nd ed. London, UK, Chapman & Hall, 1989.
27. R Development Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2011. Available from: http://www.R-project.org/
28. Chalet MD, Connors RC, Ackerman AB. Squamous cell carcinoma vs. keratoacanthoma: criteria for histologic differentiation. J Dermatol Surg 1975;1:16-7.
29. King DF, Barr RJ. Intraepithelial elastic fibers and intracytoplasmic glycogen: diagnostic aids in differentiating keratoacanthoma from squamous cell carcinoma. J Cutan Pathol 1980;7:140-8.
30. Skirpan P, Haserick JR. Keratoacanthoma; histopathologic criteria for diagnosis. Cleve Clin Q 1954;21:153-7.
31. Weedon D. Skin pathology. 2nd ed. London, Churchill Livingstone, 2002.
32. Lapins NA, Helwig EB. Perineural invasion by keratoacanthoma. Arch Dermatol 1980;116:791-3.
33. Calonje E, Jones EW. Intravascular spread of keratoacanthoma. An alarming but benign phenomenon. Am J Dermatopathol 1992;14:414-7.
34. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999;199:208-12.
35. Kern WH, McCray MK. The histopathologic differentiation of keratoacanthoma and squamous cell carcinoma of the skin. J Cutan Pathol 1980;7:318-25.
36. Klein-Szanto AJ, Barr RJ, Reiners JJ Jr, Mamrack MD. Filaggrin distribution in keratoacanthomas and squamous cell carcinoma. Arch Pathol Lab Med 1984;108: 888-90.
37. Ito Y, Kurokawa I, Nishimura K, Hakamada A, Isoda K, Yamanaka K, et al. Keratin and filaggrin expression in keratoacanthoma. J Eur Acad Dermatol Venereol 2008;22: 353-5.
38. Mukunyadzi P, Sanderson RD, Fan CY Smoller BR. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma. Mod Pathol 2002;15:45-9.
39. Papadavid E, Pignatelli M, Zakynthinos S, Krausz T, Chu AC. The potential role of abnormal E-cadherin and alpha-, beta-and gamma-catenin immunoreactivity in the determination of the biological behaviour of keratoacanthoma. Br J Dermatol 2001; 145:582-9.
40. Ho T, Horn T, Finzi E. Transforming growth factor alpha expression helps to distinguish keratoacanthomas from squamous cell carcinomas. Arch Dermatol 1991;127: 1167-71.
41. Melendez ND, Smoller BR, Morgan M. VCAM (CD-106) and ICAM (CD-54) adhesion molecules distinguish keratoacanthomas from cutaneous squamous cell carcinomas. Mod Pathol 2003;16:8-13.
42. Slater M, Barden JA. Differentiating keratoacanthoma from squamous cell carcinoma by the use of apoptotic and cell adhesion markers. Histopathology 2005;47:170-8.
43. Tataroglu C, Karabacak T, Apa DD. Betacatenin and CD44 expression in keratoacanthoma and squamous cell carcinoma of the skin. Tumori 2007;93:284-9.
44. Sleater JP, Beers BB, Stephens CA, Hendricks JB. Keratoacanthoma: a deficient squamous cell carcinoma? Study of bcl-2 expression. J Cutan Pathol 1994;21: 514-9.
45. Batinac T, Zamolo G, Coklo M, Hadzisejdic I, Stemberger C, Zauhar G. Expression of cell cycle and apoptosis regulatory proteins in keratoacanthoma and squamous cell carcinoma. Pathol Res Pract 2006;202:599-607.
46. Biesterfeld S, Josef J. Differential diagnosis of keratoacanthoma and squamous cell carcinoma of the epidermis by MIB-1 immunohistometry. Anticancer Res 2002; 22:3019-23.
47. Basta-Juzbasi A, Klenkar S, Jaki-Razumovi J, Pasi A, Loncari D. Cytokeratin 10 and Ki-67 nuclear marker expression in keratoacanthoma and squamous cell carcinoma. Acta Dermatovenerol Croat 2004;12:251-6.
48. Randall MB, Geisinger KR, Kute TE, Buss DH, Prichard RW. DNA content and proliferative index in cutaneous squamous cell carcinoma and keratoacanthoma. Am J Clin Pathol 1990;93:259-62.
49. Herzberg AJ, Kerns BJ, Pollack SV, Kinney RB. DNA image cytometry of keratoacanthoma and squamous cell carcinoma. J Invest Dermatol 1991;97:495-500.
50. Tran TA, Ross JS, Boehm JR, Carlson JA. Comparison of mitotic cyclins and cyclindependent kinase expression in keratoacanthoma and squamous cell carcinoma. J Cutan Pathol 1999;26:391-7.
51. Tran TA, Ross JS, Sheehan CE Carlson JA. Comparison of oncostatin M expression in keratoacanthoma and squamous cell carcinoma. Mod Pathol 2000;13:427-32.
52. Graham RM, MacFarlane AW, Curley RK, Nash JR. Beta 2 microglobulin expression in keratoacanthomas and squamous cell carcinoma. Br J Dermatol 1987;117:441-9.
53. Kaabipour E, Haupt HM, Stern JB, Kanetsky PA, Podolski VF, Martin AM. p16 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study. Arch Pathol Lab Med 2006;130:69-73.
54. Weedon DD, Malo J, Brooks D, Williamson R. Squamous cell carcinoma arising in keratoacanthoma: a neglected phenomenon in the elderly. Am J Dermatopathol. 2010;32:423-6.